Table 3. Clinical characteristics and outcome of 540 patients infected with major variants (n = 540).

	BA.2.10*	BA.2.38*	BA.2.75*	BA.5*	BQ.1	XBB*	Grand total
Total number of cases with history available
	17 (53.13%)	21 (46.67%)	374 (64.37%)	18 (48.65%)	10 (66.67%)	100 (58.14%)	540 (61.22%)
History of previous COVID-19 infection, p-value = 0.259
	01 (5.88%)	03 (14.29%)	51 (13.64%)	00 (00%)	01 (10%)	15 (15%)	71 (13.15%)
Symptom status at the time of sample collection, p-value = 0.071
Asymptomatic	03 (17.65%)	01 (4.76%)	28 (7.49%)	00 (00%)	03 (30%)	11 (11.%)	46 (8.52%)
Symptomatic	14 (82.35%)	20 (95.24%)	346 (92.51%)	18 (100%)	07 (70%)	89 (89%)	494 (91.48%)
Presence of comorbidity, p-value = 0.145
No comorbidity	17 (100%)	15 (71.43%)	334 (89.30%)	17 (94.44%)	10 (100%)	85 (85%)	478 (88.52%)
Presence of one condition	00 (00%)	05 (23.81%)	27 (7.22%)	01 (5.56%)	00 (00%)	11 (11%)	44 (8.15%)
Presence of two or more conditions	00 (00%)	01 (4.76%)	13 (3.48%)	00 (00%)	00 (00%)	04 (4%)	18 (3.33%)
Initial presenting symptoms
Fever	08 (57.14%)	16 (80%)	277 (80.06%)	13 (72.22%)	05 (71.43%)	65 (73.03%)	384 (77.73%)
Cough	05 (35.71%)	13 (65%)	146 (42.20%)	07 (38.89%)	04 (57.14%)	34 (38.20%)	209 (42.31%)
Fatigue/Weakness	00 (00%)	02 (10%)	78 (22.54%)	02 (11.11%)	01 (14.29%)	10 (11.24%)	93 (18.83%)
Myalgia	03 (21.43%)	00 (00%)	74 (21.39%)	01 (5.56%)	02 (28.57%)	13 (14.61%)	93 (18.83%)
Cold and rhinorrhea	07 (50%)	06 (30%)	163 (47.11%)	11 (61.11%)	03 (42.86%)	47 (52.81%)	237 (47.98%)
Headache	00 (00%)	02 (10%)	26 (7.51%)	00 (00%)	02 (28.57%)	10 (11.24%)	40 (8.10%)
Diarrhea	00 (00%)	00 (00%)	05 (1.45%)	02 (11.11%)	00 (00%)	03 (3.37%)	10 (2.02%)
Breathlessness	00 (00%)	02 (10%)	22 (6.36%)	00 (00%)	01 (14.29%)	06 (6.74%)	31 (6.28%)
Vomiting	00 (00%)	00 (00%)	09 (2.60%)	00 (00%)	00 (00%)	02 (2.25%)	11 (2.42%)
Sore throat	01 (7.14%)	01 (5%)	15 (4.34%)	01 (5.56%)	02 (28.57%)	16 (17.98%)	36 (7.29%)
Skin rash	00 (00%)	00 (00%)	03 (0.87%)	00 (00%)	00 (00%)	00 (00%)	03 (0.61%)
Chest pain	00 (00%)	00 (00%)	01 (0.29%)	00 (00%)	00 (00%)	00 (00%)	01 (0.20%)
Loss of taste	00 (00%)	00 (00%)	02 (0.58%)	00 (00%)	00 (00%)	02 (2.25%)	04 (0.81%)
Loss of smell	00 (00%)	00 (00%)	02 (0.58%)	00 (00%)	00 (00%)	01 (1.12%)	03 (0.61%)
Type of quarantine, p-value = 0.163
Home quarantine	16 (94.12%)	14 (66.67%)	280 (74.87%)	15 (83.33%)	09 (90%)	80 (80%)	414 (76.67%)
Institutional quarantine/required hospitalization	01 (5.88%)	07 (33.33%)	94 (25.13%)	03 (16.67%)	01 (10%)	20 (20%)	126 (23.33%)
Treatment, p-value = 0.067
No treatment taken	03 (17.65%)	00 (00%)	10 (2.67%)	00 (00%)	00 (00%)	04 (4%)	17 (3.15%)
Need for conservative treatment	13 (76.47%)	17 (80.95%)	330 (88.24%)	18 (100%)	10 (100%)	87 (87%)	475 (87.96%)
Need for supplemental oxygen	01 (5.88%)	04 (19.05%)	27 (7.22%)	00 (00%)	00 (00%)	05 (5%)	37 (6.85%)
Low-flow oxygen	01 (100%)	03 (75%)	23 (85.18%)	00 (00%)	00 (00%)	04 (80%)	31 (83.78%)
Intubation	00 (00%)	01 (25%)	04 (14.82%)	00 (00%)	00 (00%)	01 (20%)	06 (16.22%)
Need for antiviral agents/steroids or immunomodulatory drugs	00 (00%)	00 (00%)	07 (1.87%)	00 (00%)	00 (00%)	04 (4%)	11 (2.04%)
The outcome of disease, p-value = 0.495
Survived	17 (100%)	21 (100%)	362 (96.79%)	18 (100%)	10 (100%)	96 (96%)	524 (97.04%)
Dead	00 (00%)	00 (00%)	12 (3.21%)	00 (00%)	00 (00%)	04 (4%)	16 (2.96%)
Vaccination status, p-value = 0.181
Vaccinated with at least one dose	13 (76.47%)	18 (85.71%)	341 (91.18%)	15 (83.33%)	10 (100%)	94 (94%)	491 (90.93%)
Single dose	00 (00%)	00 (00%)	15 (4.40%)	00 (00%)	00 (00%)	02 (2.13%)	17 (3.46%)
Two doses	11 (84.62%)	16 (88.89%)	238 (69.79%)	11 (73.33%)	06 (60%)	68 (72.34%)	329 (73.27%)
Booster dose	02 (15.38%)	02 (11.11%)	88 (25.81%)	04 (26.67%)	04 (40%)	24 (25.53%)	104 (23.16%)
Not vaccinated	04 (23.53%)	03 (14.29%)	28 (7.49%)	03 (16.67%)	00 (00%)	03 (3%)	41 (7.59%)
Data not available	00 (00%)	00 (00%)	05 (1.34%)	00 (00%)	00 (00%)	03 (3%)	08 (1.48%)